Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.41 |
| ▸ | FEN1 | P39748 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11620477 | 0.78 | TRPA1 (0.39) | ALOX5APFEN1IDO1IDO2 | |
| SCHEMBL8184427 | 0.78 | DPP4 (0.47) | IDO1IDO2 | |
| Hydrochloric Acid SCHEMBL5856380 | 0.77 | DPP4 (0.46) | IDO1IDO2 | |
| SCHEMBL29512307 | 0.76 | CA1 (0.41) | ALOX5APFEN1CA1CA2CA5A | |
| SCHEMBL29505758 | 0.76 | TAAR1 (0.41) | MAOBIDO1IDO2 | |
| SCHEMBL1981166 | 0.76 | CA1 (0.41) | ALOX5APFEN1CA1CA2CA5A | |
| SCHEMBL5405687 | 0.75 | PDCD1 (0.38) | IDO1IDO2CCNT1CDK2CDK9 | |
| SCHEMBL9684688 | 0.74 | ALOX5AP (0.45) | ALOX5APFEN1CA1CA2CA5A | |
| SCHEMBL206363 | 0.72 | IDO1 (0.53) | LMNAIDO1 | |
| SCHEMBL31070194 | 0.72 | L3MBTL1 (0.45) | LMNAIDO1IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222238-A1 | Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds | BDD BEROLINA DRUG DEVELOPMENT GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
| CN-1612863-A | Deuterated substituted pyrazolylbenzylsulfonamides pharmaceutical compositions containing them and use thereof | TURICUM DRUG DEV AG (CH) | 2005-05-04 | — | — | CN | disclosed |
| CN-1612863-A | Deuterated substituted pyrazolylbenzylsulfonamides pharmaceutical compositions containing them and use thereof | TURICUM DRUG DEV AG (CH) | 2005-05-04 | — | — | CN | disclosed |
| EP-1456179-A1 | DEUTERATED SUBSTITUTED PYRAZOLYLBENZYLSULFONAMIDES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | Turicum Drug Development AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003050091-A1 | DEUTERATED SUBSTITUTED PYRAZOLYLBENZYLSULFONAMIDES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | TURICUM DRUG DEVELOPMENT AG (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222238-A1 | Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds | APC, PKD1, PKD2 | ALOX5AP 718/4885FEN1 4875/4885CA1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.